A study from Matrix Global Advisors found product hopping, which involves moving patients to reformulated versions of a medication before the patent expires, costs the US health care system billions of dollars a year. The report examined five such instances, pegging the cost of the strategy at $4.7 billion per year for Namenda, Prisolec, TriCor, Doryx and Suboxone.
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.